# Osteoporosis drugs- effectiveness and side effects | OsNovum

- Canonical URL: https://wefunder.com/feed/140658
- Entity ID: wefunder:feed_item:140658
- Published at: 2021-01-01 23:03:17 UTC
- Updated at: 2025-07-18 08:24:53 UTC

## Author
Gregory Steiner

## Subject
OsNovum

## Content
OsNovum was developed to fill a need not realized by the available osteoporosis drugs. The use antiresorptive (bone removal) osteoporosis medications have declined in use as osteoporosis diagnosis has increased. Questionable effectiveness including serious side effects have pushed many patients away from using these medications irrespective of their serious osteoporotic condition. The main class of antiresorptive osteoporosis drugs is the bisphosphonates. These drugs gained notoriety due to the development of necrosis of the jaws. It is also found that bone necrosis also increases in other areas of the body with long term use of these medications. However, in attempting to understand why jaws can develop necrosis, further serious side effects have been found that are more systemic. It has been found that bone necrosis is not only a result of the bone being compromised but the soft tissues are also compromised. Studies have found that the skin, blood vessels, and stem cells are also compromised in patients taking bisphosphonate medications and that overall wound healing is compromised in these patients. The other antiresorptive medication is denosumab with the brand name of Prolia. This medication causes similar side effects as the bisphosphonates, but new studies have found serious issues with long term effectiveness. Densoumab is effective in reducing fractures and is effective in increasing bone mass. However, to maintain effectiveness the patient must take the medication for life. If Densoumab is stopped, rapid bone loss occurs and within 12 to 24 months and the benefit of taking the medication for the past years is lost. Patients may be forced to take these medications, but no one wants to take these medications. OsNovum has no systemic side effects and when the public is aware of an option to the current osteoporosis medications, we will experience a significant demand for our therapy.